Actinogen Medical Limited (AU:ACW)
ASX:ACW
Want to see AU:ACW full AI Analyst Report?
Top Page
Actinogen Medical
(Sydney:ACW)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.05
▲(12.50% Upside)
Action:Reiterated
Date:02/14/26
The score is weighed down primarily by weak financial performance (declining revenue, persistent losses, and negative operating/free cash flow). Technical indicators also point to a bearish trend (price below key moving averages and negative MACD). Valuation is not compelling because the negative P/E reflects ongoing losses and there is no dividend yield data.
Positive Factors
Pipeline: lead candidate Xanamem
Xanamem targets large, chronic CNS indications (Alzheimer’s, MDD) via 11β-HSD1 inhibition. As a focused clinical-stage program, a successful readthrough could enable licensing or partnership revenue and long-lived commercial upside, providing durable strategic optionality.
Negative Factors
Declining revenue and negative margins
A steep revenue decline and persistent negative profitability indicate the company lacks internal commercial cash generation to fund development. Over time this undermines self-funding capacity, increases funding dependency, and signals operational challenges converting R&D into revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline: lead candidate Xanamem
Xanamem targets large, chronic CNS indications (Alzheimer’s, MDD) via 11β-HSD1 inhibition. As a focused clinical-stage program, a successful readthrough could enable licensing or partnership revenue and long-lived commercial upside, providing durable strategic optionality.
Read all positive factors
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$147.24M
Dividend YieldN/A
Average Volume (3M)6.03M
Price to Earnings (P/E)―
Beta (1Y)-0.39
Revenue GrowthN/A
EPS Growth-64.71%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,591,209,200
10 Day Avg. Volume4,755,726
30 Day Avg. Volume6,028,147
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)3.74
Price to Sales (P/S)12.48
P/FCF Ratio-9.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.50M
Actinogen Medical Business Overview & Revenue Model
Company Description
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is...
How the Company Makes Money
Actinogen Medical is a clinical-stage biotechnology company and, based on publicly available information, it does not appear to generate material recurring revenue from product sales. Its primary source of funding is typically capital raising (e.g...
Actinogen Medical Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49M | 5.49M | 9.93M | 4.89M | 3.64M | 1.98M |
| Gross Profit | 5.28M | 5.49M | 9.93M | 4.48M | 3.24M | 1.60M |
| EBITDA | -19.88M | -15.01M | -12.84M | -15.22M | -12.72M | -5.35M |
| Net Income | -17.91M | -14.73M | -13.04M | -10.75M | -9.50M | -3.92M |
Balance Sheet | ||||||
| Total Assets | 10.60M | 24.48M | 21.31M | 15.21M | 23.31M | 18.38M |
| Cash, Cash Equivalents and Short-Term Investments | 6.53M | 16.50M | 9.45M | 8.46M | 16.37M | 13.42M |
| Total Debt | 366.31K | 3.26M | 319.07K | 86.93K | 165.27K | 236.44K |
| Total Liabilities | 2.23M | 6.15M | 1.62M | 1.80M | 1.57M | 920.32K |
| Stockholders Equity | 8.37M | 18.34M | 19.70M | 13.41M | 21.74M | 17.46M |
Cash Flow | ||||||
| Free Cash Flow | -16.45M | -7.59M | -16.96M | -8.73M | -9.52M | -1.73M |
| Operating Cash Flow | -16.41M | -7.56M | -16.95M | -8.70M | -9.52M | -1.72M |
| Investing Cash Flow | -38.37K | -38.02K | -8.16K | -36.60K | -2.94K | -6.19K |
| Financing Cash Flow | 116.65K | 14.65M | 17.95M | 824.62K | 12.42M | 10.11M |
Actinogen Medical Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.05
Negative
0.04
Positive
Market Momentum
<0.01
Negative
54.37
Neutral
69.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACW, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.37 is Neutral, neither overbought nor oversold. The STOCH value of 69.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ACW.
Actinogen Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$1.62B | 38.25 | 9.20% | ― | -69.69% | -78.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$32.92M | -5.38 | -19.10% | ― | ― | -285.37% | |
45 Neutral | AU$63.64M | -10.19 | -104.56% | ― | ― | 57.89% | |
43 Neutral | AU$147.24M | -4.28 | -134.14% | ― | ― | -64.71% | |
41 Neutral | AU$108.75M | -2.12 | -30.19% | ― | ― | 62.50% | |
39 Underperform | AU$5.95M | -1.05 | 56.41% | ― | -99.31% | 90.20% |
* Healthcare Sector Average
AU:ACW
Actinogen Medical
0.04
0.02
86.36%
AU:ENP
Tryptamine Therapeutics
0.04
<0.01
11.43%
AU:NEU
Neuren Pharmaceuticals Limited
12.79
0.16
1.27%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:ZLD
Zelira Therapeutics
0.50
0.09
21.95%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.10
0.05
98.00%
Actinogen Medical Corporate Events
Actinogen CEO Exercises Options as Key Alzheimer’s Trial Milestone Nears
May 13, 2026
Actinogen Medical has highlighted that two tranches of unlisted options, ACWOPT10 and ACWOPT11, each exercisable at $0.0375, are due to expire in September 2026, and reminded holders to allow sufficient time for exercise and payment processing. Th...
Actinogen CEO Steven Gourlay Boosts Shareholding Through Option Exercise
May 13, 2026
Actinogen Medical has disclosed a change in director Dr Steven Gourlay’s interests following the exercise of unlisted options into fully paid ordinary shares. Gourlay converted a total of 2,442,647 unlisted options, increasing both his direc...
Actinogen Medical Seeks ASX Quotation for 2.44m New Shares
May 13, 2026
Actinogen Medical Limited, an Australian biotechnology company listed on the ASX under ticker ACW, has issued additional fully paid ordinary shares as part of its ongoing capital management and corporate development activities.The company has appl...
Actinogen Seeks ASX Quotation for 60,000 New Shares
May 11, 2026
Actinogen Medical Limited has applied to the ASX for quotation of 60,000 new ordinary fully paid shares, issued on 10 May 2026 under its ticker ACW. The additional securities arise from the exercise or conversion of existing options or other conve...
Actinogen cancels 2.8m shares under employee scheme buy-back
May 3, 2026
Actinogen Medical has notified the market of the cessation of 2,833,335 ordinary fully paid shares, following their cancellation under an employee share scheme buy-back. The adjustment to issued capital reflects ongoing management of its employee ...
Actinogen extends cash runway as pivotal Alzheimer’s trial advances
Apr 29, 2026
Actinogen Medical reported progress on its pivotal XanaMIA phase 2b/3 Alzheimer’s trial, with an independent Data Monitoring Committee recommending the study continue unchanged after a positive interim analysis of safety and futility. The 24...
Actinogen extends cash runway as pivotal Alzheimer’s trial advances
Apr 29, 2026
Actinogen Medical reported steady progress in its pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial, with an independent data monitoring committee recommending the study continue unchanged after a positive interim analysis, and topline re...
Actinogen Medical Announces Employee Share Scheme Buy-Back
Apr 2, 2026
Actinogen Medical has notified the market that it will conduct an employee share scheme buy-back of its ordinary fully paid shares listed on the ASX under the ticker ACW. The move signals an adjustment to its employee equity arrangements and capit...
Actinogen opens long-term Xanamem extension in pivotal Alzheimer’s trial
Apr 1, 2026
Actinogen Medical has begun the open-label extension phase of its XanaMIA Phase 2b/3 Alzheimer’s trial, allowing all former and current randomized-phase participants in Australia and the U.S. to receive active Xanamem 10 mg once daily for up...
Actinogen Director Geoffrey Brooke Increases Stake via Placement
Mar 26, 2026
Actinogen Medical has disclosed a change in the interests of director Dr Geoffrey Brooke following the issue of director placement shares. After shareholder approval on 18 March 2026, Brooke acquired 1,357,857 fully paid ordinary shares indirectly...
Actinogen issues director placement shares after shareholder approval
Mar 26, 2026
Actinogen Medical has issued 15,880,953 new fully paid ordinary shares at $0.042 each to its directors, following shareholder approval of a director placement earlier in March. The company confirmed it has met its continuous disclosure and financi...
Actinogen Medical Seeks ASX Quotation for 15.9 Million New Shares
Mar 26, 2026
Actinogen Medical has applied for quotation of 15,880,953 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of March 26, 2026. The securities form part of a previously announced transaction, signalling an exp...
Actinogen secures $16.8m to fund pivotal Alzheimer’s trial beyond topline results
Mar 18, 2026
Actinogen Medical shareholders approved all six resolutions at a general meeting, including the issuance of placement shares to CEO Dr Steven Gourlay and non-executive directors, who collectively subscribed for A$667,000 at 4.2 cents per share. Th...
Actinogen Extends CEO Loan-Funded Incentive to Support Ongoing Equity Alignment
Mar 15, 2026
Actinogen Medical has amended the loan-funded long-term incentive arrangements for CEO Dr Steven Gourlay by extending the term of a secured, interest-free, limited recourse loan linked to his Loan Plan Shares by two years. The extension applies to...
Actinogen Medical Seeks Quotation for Additional ASX Shares
Mar 5, 2026
Actinogen Medical has applied for quotation on the ASX of 62,014 new ordinary fully paid shares, to be traded under its existing ticker ACW. The securities, issued on March 5, 2026 following the exercise or conversion of existing options or other ...
Actinogen Medical Seeks ASX Quotation for Over 113 Million New Shares
Mar 1, 2026
Actinogen Medical Limited has applied for quotation on the ASX of 113,617,184 new ordinary fully paid shares, expanding its listed securities under the code ACW. The issuance, dated 2 March 2026, forms part of previously announced transactions and...
Actinogen secures $16.8m to fund pivotal Alzheimer’s trial
Feb 27, 2026
Actinogen Medical has completed a $16.8 million capital raise, including $4.8 million from a share purchase plan offered to existing shareholders on the same terms as a prior placement. The new funding lifts its pro forma 31 December 2025 cash bal...
Actinogen Medical Adds 67,499 New Shares to ASX Quotation
Feb 26, 2026
Actinogen Medical Limited, an ASX-listed biotechnology company trading under the code ACW, has applied for quotation of additional ordinary fully paid shares. The move marginally increases its listed equity base, reflecting the conversion or exerc...
Actinogen Medical Widens Half-Year Loss as R&D Spending Rises
Feb 26, 2026
Actinogen Medical reported a modest decline in revenue from ordinary activities for the half year to 31 December 2025, with income of $232,920, largely from interest on cash and short-term deposits. The company remains in an investment phase, post...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.